Concerta (Methylphenidate): ADHD Uses and Safety

What Concerta 18 mg is used for

Concerta 18 mg contains methylphenidate hydrochloride in an extended-release oral tablet for attention-deficit/hyperactivity disorder. The reviewed US label covers patients aged six to sixty-five; the UK Concerta XL label describes use in children from six years and adults within a comprehensive treatment programme. Eligibility still depends on a specialist assessment. Concerta is not interchangeable with every immediate-release or modified-release methylphenidate product simply because the active ingredient or milligram number looks similar.

Handling and routine monitoring

The tablet must be swallowed whole; chewing, dividing or crushing can interfere with its release system. An empty tablet shell may appear in the stool. Reduced appetite, sleep difficulty, headache, stomach discomfort and weight loss are common concerns. Blood pressure and pulse can rise. Prescribers monitor cardiovascular status, mood and behaviour, and growth in children. Discuss existing heart disease, tics, glaucoma or other significant medical conditions before treatment; the UK and US labels differ in how some restrictions are stated.

Interactions and substance-related risks

Monoamine oxidase inhibitors and the specified period after stopping them are incompatible with Concerta because of hypertensive-crisis risk. Medicines that raise blood pressure, antihypertensives and certain psychiatric treatments also require review. Serotonin syndrome has been reported with serotonergic combinations. Tell the anaesthetic team about methylphenidate before surgery because some anaesthetics can cause sudden cardiovascular effects when combined with it. The UK product information advises avoiding alcohol; laboratory findings about alcohol and tablet release do not establish a predictable clinical effect for an individual.

When urgent review is needed

Stimulants carry risks of misuse, addiction and overdose, so keep tablets secure and never share them. Chest pain, fainting, unexplained breathlessness, new hallucinations or mania, a prolonged painful erection or a serious allergic reaction require prompt assessment. New severe agitation with fever, sweating or abnormal muscle movements also needs urgent evaluation. Pregnancy and breastfeeding require a personal benefit-risk discussion. A clinician should review effectiveness, adverse effects and the continuing need for treatment; this page does not supply a starting dose, conversion table or withdrawal schedule.

Sources and scope

• Concerta extended-release methylphenidate tablets - US prescribing information - US label revised April 2026; DailyMed updated 20 April 2026
• Concerta XL 18 mg prolonged-release tablets - UK Summary of Product Characteristics - Text revised 6 November 2025; emc updated 21 November 2025

Source check: 30 October 2026. This records a source check, not a clinical review by a doctor or pharmacist. This summary does not replace the current leaflet supplied with your medicine or an individual treatment review.